160 related articles for article (PubMed ID: 23749546)
1. Trials show delayed recurrence in ovarian cancer.
Bender E
Cancer Discov; 2013 Jun; 3(6):OF8. PubMed ID: 23749546
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic modification boosts ovarian cancer vaccination.
Benmaamar R
Lancet Oncol; 2014 Feb; 15(2):e55. PubMed ID: 24627909
[No Abstract] [Full Text] [Related]
3. Follow-up of epithelial ovarian cancer: overdue for a major rethink.
Hoskins P
Curr Oncol Rep; 2013 Jun; 15(3):204-6. PubMed ID: 23483376
[No Abstract] [Full Text] [Related]
4. The role of heated intraperitoneal chemotherapy (HIPEC) in ovarian cancer: hope or hoax?
Herzog TJ
Ann Surg Oncol; 2012 Dec; 19(13):3998-4000. PubMed ID: 22833000
[No Abstract] [Full Text] [Related]
5. [Treatment of recurrent ovarian cancer].
Kitao A; Matsumoto K
Nihon Rinsho; 2012 Jun; 70 Suppl 4():628-33. PubMed ID: 23156322
[No Abstract] [Full Text] [Related]
6. Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials.
Korkmaz T; Seber S; Basaran G
Crit Rev Oncol Hematol; 2016 Feb; 98():180-8. PubMed ID: 26603345
[TBL] [Abstract][Full Text] [Related]
7. Specific immunotherapy in ovarian cancer: a systematic review.
Aalipour S; Zoghi S; Khalili N; Hirbod-Mobarakeh A; Emens LA; Rezaei N
Immunotherapy; 2016 Oct; 8(10):1193-204. PubMed ID: 27605068
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy of cytotoxic t-lymphocyte-associated antigen 4 (ctla-4) and programmed death 1 (pd 1) blocker, check point inhibitors for treatment of patients with advanced and recurrent epithelial ovarian cancer.
Farghaly SA
Eur J Gynaecol Oncol; 2017; 38(1):7-9. PubMed ID: 29767856
[TBL] [Abstract][Full Text] [Related]
9. Future directions in the management of epithelial ovarian cancer.
Blagden S; Gabra H
Future Oncol; 2008 Jun; 4(3):403-11. PubMed ID: 18518765
[TBL] [Abstract][Full Text] [Related]
10. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer.
Joly F; Hilpert F; Okamoto A; Stuart G; Ochiai K; Friedlander M;
Eur J Cancer; 2017 Jun; 78():133-138. PubMed ID: 28448857
[TBL] [Abstract][Full Text] [Related]
11. A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer.
Chiva LM; Gonzalez-Martin A
Gynecol Oncol; 2015 Jan; 136(1):130-5. PubMed ID: 25434634
[TBL] [Abstract][Full Text] [Related]
12. FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper.
Herzog TJ; Ison G; Alvarez RD; Balasubramaniam S; Armstrong DK; Beaver JA; Ellis A; Tang S; Ford P; McKee A; Gershenson DM; Kim G; Monk BJ; Pazdur R; Coleman RL
Gynecol Oncol; 2017 Oct; 147(1):3-10. PubMed ID: 28844539
[No Abstract] [Full Text] [Related]
13. [Pay more attention to the surveillance and deal with the recurrence in ovarian cancer].
Shen K
Zhonghua Fu Chan Ke Za Zhi; 2003 Nov; 38(11):657-8. PubMed ID: 14989220
[No Abstract] [Full Text] [Related]
14. Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.
Fagotti A; Petrillo M; Costantini B; Fanfani F; Gallotta V; Chiantera V; Turco LC; Bottoni C; Scambia G
Gynecol Oncol; 2014 Feb; 132(2):303-6. PubMed ID: 24378877
[TBL] [Abstract][Full Text] [Related]
15. Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study.
Ferrero A; Ditto A; Giorda G; Gadducci A; Greggi S; Daniele A; Fuso L; Panuccio E; Scaffa C; Raspagliesi F; Sismondi P; Biglia N
Eur J Surg Oncol; 2014 Jul; 40(7):891-8. PubMed ID: 24378007
[TBL] [Abstract][Full Text] [Related]
16. How I treat ovarian cancer in older women.
Lichtman SM
J Geriatr Oncol; 2014 Jul; 5(3):223-9. PubMed ID: 24954887
[TBL] [Abstract][Full Text] [Related]
17. Conservative treatment of early stage ovarian cancer: oncological and fertility outcomes.
Zapardiel I; Diestro MD; Aletti G
Eur J Surg Oncol; 2014 Apr; 40(4):387-93. PubMed ID: 24368049
[TBL] [Abstract][Full Text] [Related]
18. Epithelial ovarian cancer.
Morgan RJ; Alvarez RD; Armstrong DK; Boston B; Burger RA; Chen LM; Copeland L; Crispens MA; Gershenson D; Gray HJ; Grigsby PW; Hakam A; Havrilesky LJ; Johnston C; Lele S; Matulonis UA; O'Malley DM; Penson RT; Remmenga SW; Sabbatini P; Schilder RJ; Schink JC; Teng N; Werner TL;
J Natl Compr Canc Netw; 2011 Jan; 9(1):82-113. PubMed ID: 21233246
[No Abstract] [Full Text] [Related]
19. New paradigms in the surgical and adjuvant treatment of ovarian cancer.
Hodeib M; Eskander RN; Bristow RE
Minerva Ginecol; 2014 Apr; 66(2):179-92. PubMed ID: 24848076
[TBL] [Abstract][Full Text] [Related]
20. Patterns of recurrence and role of pelvic radiotherapy in ovarian clear cell adenocarcinoma.
Macrie BD; Strauss JB; Helenowski IB; Rademaker A; Schink JC; Lurain JR; Small W
Int J Gynecol Cancer; 2014 Nov; 24(9):1597-602. PubMed ID: 25275661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
